Last chance to submit your nominations for the FiercePharma Marketing Awards
Applications are due at midnight tonight. Submit your nominations today.
New data from analysts at SSR show list prices haven't been growing as fast as they were—and the amount payers actually shell out is falling.
Keytruda-Lenvima combo wins simultaneous OKs. Eisai and Biogen ditch second BACE drug. Sanofi is leaving Bangladesh. Henlius raises $410 million.
Best practices manufacturers can leverage to ensure accurate and timely data is available at launch and beyond
With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.
Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.
Alongside long-term data showing patients were still benefiting from Zolgensma, Novartis said a trial patient's death wasn't related to the therapy.
Novartis has gotten out in front of an FDA, and its competitors, by halting worldwide distribution of its generic Zantac.
GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.
It's official: Pharma faces an aggressive plan for price negotiation on top brands, price-hike rollbacks and more. But does the bill stand a chance?
Months after the FDA demanded Lupin act on failures at an Indian plant, the drugmaker may have known a reckoning was coming. They were right.
Roche has spent years reprioritizing its manufacturing spending, and as part of that process, it's exiting a small molecule site in Ireland.